Carbapenem-resistant Enterobacteriaceae Testing Market
Carbapenem-resistant Enterobacteriaceae Testing Market Study by Modified Hodge and Minimal Inhibitory Concentration in Hospitals, Ambulatory Surgical Centers, Intensive Care Units, and Others From 2024 to 2034
Analysis of Carbapenem-resistant Enterobacteriaceae Testing Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Carbapenem-resistant Enterobacteriaceae Testing Market Outlook (2024 to 2034)
The global carbapenem-resistant enterobacteriaceae testing market is estimated at a value of US$ 4.25 billion in 2024 and is forecasted to reach a size of US$ 8.89 billion by 2034-end. Worldwide demand is projected to advance at a 7.7% CAGR from 2024 to 2034.
One key factor driving the market growth is the increasing incidences of infections brought on by enterobacteriaceae that are resistant to carbapenem. Serious health problems resulting from CRE infections make accurate diagnosis and treatment of these cases imperative. To facilitate timely treatment and infection control measures, CRE needs to be identified quickly in clinical settings. Quick diagnostic tests shorten the time it takes to get findings, which enhances patient outcomes and slows the spread of infections in medical institutions. Diagnostic technology advancements, such as next-generation sequencing and PCR are improving the sensitivity and specificity of CRE testing. These developments are facilitating the utilization of effective testing procedures at laboratories, which is further driving the market expansion.
North America is analyzed to account for 37.7% of global market share in 2024. The high prevalence of antibiotic-resistant illnesses and strong healthcare infrastructure in this region, especially the United States are making it a lucrative market. The Western Europe region is estimated to generate a turnover of US$ 925.51 million in the current year (2024). Demand for carbapenem-resistant enterobacteriaceae testing is increasing in Western European countries, including the United Kingdom, Germany, and France due to the rising number of multidrug-resistant infection cases.
By test type, modified hodge carbapenem-resistant enterobacteriaceae testing is holding a 49.5% portion of the overall revenue in 2024 and is further forecasted to increase to 50.5% by the end of 2034. Demand for this test is high due to its reliability, simplicity, and cost-effectiveness. As a phenotypic test, the MHT is widely used in clinical laboratories to identify carbapenemase-producing organisms, which are responsible for the resistance observed in CRE infections.
| Report Attributes | Details |
|---|---|
| Carbapenem-resistant Enterobacteriaceae Testing Market Size (2024E) | US$ 4.25 Billion |
| Forecasted Market Value (2034F) | US$ 8.89 Billion |
| Global Market Growth Rate (2024 to 2034) | 7.7% CAGR |
| North America Market Share (2024E) | 37.7% |
| Western Europe Market Value (2024E) | US$ 925.51 Million |
| South Asia & Pacific Market Growth Rate (2024 to 2034) | 9.6% CAGR |
| Modified Hodge Segment Value (2034F) | US$ 4.49 Billion |
| Hospitals Segment Value (2034F) | US$ 4.41 Billion |
| Key Companies Profiled | TBA; SolGent Co., Ltd.; ELITechGroup; ALIFAX S.r.l.; bioMérieux, Inc.; Cepheid; Siemens Healthineers; Roche Diagnostics; Thermo Fisher Scientific; Abbott Laboratories; Merck Group; Hoffmann-La Roche |
Enterobacteriaceae are a family of germs that most commonly live in a person’s bowel without causing any disease. Carbapenems are strong antibiotics that are commonly used to treat serious infections. A few enterobacteriaceaea have gained resistance to these antibiotics. These are called Carbapenem-resistant Enterobacteriaceae. Carbapenem-resistant Enterobacteriaceae testing is considered to be a gram-negative pathogen testing. Common gram-negative pathogens include Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumonia, Enterobacter aerogenes, and Acinetobacterbaumannii.
These gram-negative pathogens are mediated and treated by transferable carbapenemase-encoding genes. A few infections caused by carbapenem-resistant Enterobacteriaceae outside the bowel include wound infection, urinary tract infection (UTI), and pneumonia. People prone to Carbapenem-resistant enterobacteriaceae include people admitted to hospitals or other healthcare settings. According to The Centers for Disease Control and Prevention (CDC), around 2 million people are infected by antibiotic-resistant organisms every year, which further leads to approximately 23,000 deaths annually.
The mortality rates are also high, ranging from 40%-50%. Two major factors responsible for this kind of infection are the use of mechanical ventilation and the use of beta-lactam antibiotics. Beta-lactam antibiotics include Cephalosporins, Penicillins, monobactams, and Carbapenems. Carbapenem-resistant enterobacteriaceae testing includes disc diffusion or automated systems, selective agar Carbapenem-resistant enterobacteriaceae testing, minimal inhibitory concentration (MIC) for Carbapenem-resistant enterobacteriaceae testing, synergy Carbapenem-resistant enterobacteriaceae testing, modified Hodge tests, whole genome sequencing, spectrometrics, and various other molecular methods.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Carbapenem-resistant Enterobacteriaceae Testing Market: Drivers
People admitted to any healthcare setting for medical care are more prone to infection and go for Carbapenem-resistant enterobacteriaceae testing than healthy people. Increase in the number of people requiring inpatient medical assistance, a growing number of healthcare facilities, an increased number of complex surgeries, multiple uses of several antibiotics, and a rise in the use of medical devices in the body, such as urinary catheters, intravenous catheters, and ventilators, are few of the major factors responsible for growth in the Carbapenem-resistant enterobacteriaceae testing market.
Growing awareness about the prevention of Carbapenem resistance and increased efforts by governments through the implementation of infection prevention and control measures might hinder the growth of the Carbapenem-resistant enterobacteriaceae testing market during the forecast period.
Carbapenem-resistant Enterobacteriaceae Testing Market: Overview
In Carbapenem-resistant Enterobacteriaceae Testing, Modified Hodge tests are anticipated to be one of the leading test types for Carbapenem-resistant enterobacteriaceae testing because of the high accuracy of test results. These tests are easy to perform and easily performed in a routine laboratory, which makes them more feasible and thus, one of the leading test types in the carbapenem-resistant enterobacteriaceae testing market.
Molecular testing detects the resistance mechanism whereas phenotypic tests detect the in-vitro activity of carbapenemase enzyme. Healthcare settings, such as nursing homes and acute care centers, where constant medical care is required for a longer duration of time are more prone to CRE and thus, the demand for Carbapenem-resistant enterobacteriaceae testing is higher in these settings.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Carbapenem-resistant Enterobacteriaceae Testing Market: Regional Outlook
According to The Centers for Disease Control and Prevention (CDC), by 2013 Carbapenem-resistant enterobacteriaceae was found in almost 42 states. CDC also stated that the enterobacteriaceae proportion of Carbapenem-resistance has consistently increased and has increased four-fold in the past ten years. During the early 2000s, CRE was rare in the North American region.
However, the breakout of CRE in the northeast spread through the US, thereby boosting the market for Carbapenem-resistant enterobacteriaceae testing in the region. The Asia Pacific market for Carbapenem-resistant enterobacteriaceae testing is also expected to expand during the forecast period because of the detection of different classes of carbapenemase.
Carbapenem-resistant Enterobacteriaceae Testing Market: Key Players
Some of major participants operating in the Carbapenem-resistant Enterobacteriaceae Testing market are
- TBA
- SolGent Co., Ltd.
- ELITechGroup
- ALIFAX S.r.l.
- bioMérieux, Inc.
- Cepheid
- Siemens Healthineers
- Roche Diagnostics
- Thermo Fisher Scientific
- Abbott Laboratories
- Merck Group
- Hoffmann-La Roche
The report is a compilation of first-hand information, qualitative and quantitative assessments by industry analysts, and inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macro-economic indicators, and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
The report covers an exhaustive analysis on
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Technology
- Value Chain
Regional analysis includes
- North America
- US
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Chile
- Peru
- Rest of LATAM
- Europe
- EU – 4 (Germany, France, Italy, Spain)
- UK
- BENELUX (Belgium, Netherlands, Luxemburg)
- NORDIC (Norway, Denmark, Iceland, Sweden)
- Eastern Europe (Poland, Ukraine, Czech Rep. Etc.)
- Rest of Europe
- CIS & Russia
- Japan
- APEJ
- Greater China
- India
- Korea
- ASEAN Countries
- Rest of APEJ
- Middle East & Africa
- GCC Countries
- Turkey
- Iran
- Israel
- South Africa
- Rest of MEA
Report Highlights
- Detailed overview of parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- Historical, current and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint.
Segmentation of Carbapenem-resistant Enterobacteriaceae Testing Market Research
-
By Test Type :
- Modified Hodge
- Minimal Inhibitory Concentration
- Others
-
By End User :
- Hospitals
- Ambulatory Surgical Centers
- Intensive Care Units
- Clinics
- Nursing Homes
- Long-Term Acute Care Centers
-
By Region :
- North America
- Western Europe
- Eastern Europe
- Latin America
- East Asia
- South Asia & Pacific
- Middle East & Africa
Table of Content
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis and Forecast, including Historical Analysis and Future Projections 5. Pricing Analysis 6. Global Market Analysis and Forecast 6.1. Test Type 6.2. End Users 7. Global Market Analysis and Forecast, By Test Type 7.1. Modified Hodge Carbapenem-resistant Enterobacteriaceae Testing 7.2. Minimal Inhibitory Concentration Carbapenem-resistant Enterobacteriaceae Testing 7.3. Other Types of Carbapenem-resistant Enterobacteriaceae Testing 8. Global Market Analysis and Forecast, By End Users 8.1. Hospitals 8.2. Ambulatory Surgical Centers 8.3. Intensive Care US$ Mns 8.4. Clinics 8.5. Nursing Homes 8.6. Long Term Acute Care Centers 8.7. Others 9. Global Market Analysis and Forecast, By Region 9.1. North America 9.2. Latin America 9.3. Western Europe 9.4. Eastern Europe 9.5. Asia Pacific 9.6. East Asia 9.7. MEA 10. North America Sales Analysis and Forecast, by Key Segments and Countries 11. Latin America Sales Analysis and Forecast, by Key Segments and Countries 12. Western Europe Sales Analysis and Forecast, by Key Segments and Countries 13. Eastern Europe Sales Analysis and Forecast, by Key Segments and Countries 14. Asia Pacific Sales Analysis and Forecast, by Key Segments and Countries 15. East Asia Sales Analysis and Forecast, by Key Segments and Countries 16. MEA Sales Analysis and Forecast, by Key Segments and Countries 17. Sales Forecast by Test Type and End Users for 30 Countries 18. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 19. Company Profile 19.1. TBA 19.2. SolGent Co., Ltd. 19.3. ELITechGroup 19.4. ALIFAX S.r.l. 19.5. bioMérieux, Inc
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 1: Global Market US$ Mn Forecast by Region
Table 2: Global Market US$ Mn Forecast by Test Type
Table 3: Global Market US$ Mn Forecast by End Users
Table 4: North America Market US$ Mn Forecast by Country
Table 5: North America Market US$ Mn Forecast by Test Type
Table 6: North America Market US$ Mn Forecast by End Users
Table 7: Latin America Market US$ Mn Forecast by Country
Table 8: Latin America Market US$ Mn Forecast by Test Type
Table 9: Latin America Market US$ Mn Forecast by End Users
Table 10: Western Europe Market US$ Mn Forecast by Country
Table 11: Western Europe Market US$ Mn Forecast by Test Type
Table 12: Western Europe Market US$ Mn Forecast by End Users
Table 13: Eastern Europe Market US$ Mn Forecast by Country
Table 14: Eastern Europe Market US$ Mn Forecast by Test Type
Table 15: Eastern Europe Market US$ Mn Forecast by End Users
Table 16: Asia Pacific Market US$ Mn Forecast by Country
Table 17: Asia Pacific Market US$ Mn Forecast by Test Type
Table 18: Asia Pacific Market US$ Mn Forecast by End Users
Table 19: East Asia Market US$ Mn Forecast by Country
Table 20: East Asia Market US$ Mn Forecast by Test Type
Table 21: East Asia Market US$ Mn Forecast by End Users
Table 22: MEA Market US$ Mn Forecast by Country
Table 23: MEA Market US$ Mn Forecast by Test Type
Table 24: MEA Market US$ Mn Forecast by End Users
Table 25: Region Market US$ Mn Forecast by Country
Table 26: Region Market US$ Mn Forecast by Test Type
Table 27: Region Market US$ Mn Forecast by End Users
Table 28: North America Market US$ Mn Forecast by Country
Table 29: North America Market US$ Mn Forecast by Test Type
Table 30: North America Market US$ Mn Forecast by End Users
Table 31: Latin America Market US$ Mn Forecast by Country
Table 32: Latin America Market US$ Mn Forecast by Test Type
Table 33: Latin America Market US$ Mn Forecast by End Users
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 1: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Test Type
Figure 2: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End Users
Figure 3: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Region
Figure 4: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Test Type
Figure 5: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End Users
Figure 6: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 7: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Test Type
Figure 8: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End Users
Figure 9: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 10: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Test Type
Figure 11: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End Users
Figure 12: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 13: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Test Type
Figure 14: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End Users
Figure 15: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 16: Asia Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Test Type
Figure 17: Asia Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End Users
Figure 18: Asia Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 19: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Test Type
Figure 20: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End Users
Figure 21: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 22: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Test Type
Figure 23: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End Users
Figure 24: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 25: Region Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Test Type
Figure 26: Region Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End Users
Figure 27: Region Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 28: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Test Type
Figure 29: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End Users
Figure 30: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 31: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Test Type
Figure 32: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End Users
Figure 33: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How big is the carbapenem-resistant enterobacteriaceae testing market in 2024?
The global market for carbapenem-resistant enterobacteriaceae testing is estimated at US$ 4.25 billion in 2024.
What is the future of carbapenem-resistant enterobacteriaceae testing?
Worldwide demand for carbapenem-resistant enterobacteriaceae testing is projected to reach US$ 8.89 billion by 2034.
What is the demand growth projection for the global market?
Worldwide demand for carbapenem-resistant enterobacteriaceae testing is forecasted to increase at a CAGR of 7.7% from 2024 to 2034.
Carbapenem-resistant Enterobacteriaceae Testing Market